The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

BACKGROUND: Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic effects, yet clinical data are scarcely available. DESIGN AND METHODS: A prospect...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Diabetol
Hlavní autoři: Younis, Arwa, Eskenazi, Dana, Goldkorn, Ronen, Leor, Jonathan, Naftali-Shani, Nili, Fisman, Enrique Z., Tenenbaum, Alexander, Goldenberg, Ilan, Klempfner, Robert
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5440983/
https://ncbi.nlm.nih.gov/pubmed/28532406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0551-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky